Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07400588 · ClinicalTrials.gov registry record · Phase 2

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

A Phase 2 study of Obesity and Weight Loss, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
17
Study locations

NCT07400588 is a Phase 2 study of Obesity and Weight Loss that is actively recruiting participants, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 50 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07400588, a Phase 2 study of Obesity and Weight Loss, is actively recruiting participants, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).

Conditions Studied

Obesity Weight Loss Obese Obesity Type 2 Diabetes Mellitus

Interventions

  • DRUG Placebo
  • DRUG Aleniglipron

Study Locations (17)

Texas

  • Research Site - Austin
  • Research Site - Austin
  • Research Site - DeSoto
  • Research Site - Houston
  • Research Site - Mesquite
  • Research Site - San Antonio
  • Research Site - San Antonio
  • Research Site - San Antonio
  • Research Site - Tomball

California

  • Research Site - Lake Forest
  • Research Site - Lomita

Tennessee

  • Research Site - Chattanooga
  • Research Site - Knoxville

Alabama

  • Research Site - Anniston

Missouri

  • Research Site - Hazelwood

Ohio

  • Research Site - Columbus

South Carolina

  • Research Site - Moncks Corner

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-12-01
Est. Completion 2026-11
Phase Phase 2

Sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07400588

The ClinicalTrials.gov registry entry for NCT07400588 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The listed sponsor is Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07400588 reports 17 study locations spanning 7 distinct geographic areas - top geographies include Texas, California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT07400588 about?

NCT07400588 is a clinical study titled "Aleniglipron Phase 2 in Type 2 Diabetes Mellitus". The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).

What is the current status of trial NCT07400588?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-12-01. Estimated completion is 2026-11.

What conditions does trial NCT07400588 study?

This clinical trial studies the following conditions: Obesity, Weight Loss, Obese, Obesity Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT07400588?

The interventions under investigation include: Placebo (DRUG), Aleniglipron (DRUG).

Who is sponsoring clinical trial NCT07400588?

This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07400588 being conducted?

This trial has 17 study locations across Alabama, California, Missouri, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Weight Loss

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.